Moderna's RSV vaccine has experienced safety concerns, leading the FDA to call for more research. Alongside this, pediatric RSV vaccine trials are on hold. Nevertheless, Moderna's mRNA technologies have garnered significant interest, with the Gates Foundation betting big, and shows promise in protecting against current strains of avian influenza. Over the past three months, Moderna's stock has dropped 39%, leading to debate over whether to buy the dip. Moderna has received $176 million from the U.S government for the development of an mRNA bird flu pandemic vaccine. Amidst legal battles regarding mRNA vaccine patents, Moderna has emerged with a surprise profit. Phase III trials of Moderna's mRNA norovirus vaccine have begun. FDA approval has been granted for Moderna’s mRNA RSV vaccine for older adults. Northwestern University is suing Moderna for COVID mRNA vaccine royalties. Moderna has released positive Phase III data for a combined Covid-19/Influenza mRNA vaccine alongside updated 2024–2025 COVID-19 vaccines. However, Moderna has faced a financial setback in its quest to establish a Kenyan mRNA Vaccine Plant. The U.S Government has awarded Moderna an additional $176 million for mRNA Bird Flu Vaccine development.
Moderna MRNA News Analytics from Fri, 01 Apr 2022 20:22:24 GMT to Fri, 27 Dec 2024 08:44:16 GMT -
Rating 5
- Innovation 8
- Information 10
- Rumor 4
